MTAP and cancer: In parallel, further investigation into potential resistance mechanisms, such as compensatory metabolic pathways or altered nutrient uptake, as well as the safety considerations identified in early-phase clinical trials, will be critical for advancing glutaminase inhibitors toward therapeutic application in MTAP-deficient cancers.